Global Drug-induced Cardiotoxicity Market By Indications (Left Ventricle Dysfunction, Anthracyclines, Trastuzumab, Lapatinib, ABL Inhibitors, Bortezomib, Others), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Drug-induced cardiotoxicity is a major cause of compound failure in preclinical and clinical trials. It is one of the most significant side-effects associated with the development of new pharmaceuticals, and it is also one of the most common toxic consequences caused by several drugs. Cardiotoxicity is not limited to anti-cancer drugs; nearly every therapeutic medication type can cause unforeseen cardiotoxicity.

Cardiotoxicity caused by persistently administered medications, such as neurologic/psychiatric treatments and anticancer chemotherapeutic agents, are major issues, since toxicity may not be apparent until the drug or its metabolites have accumulated for a long time.

Drug-induced cardiotoxicity risk, including QT interval prolongation, is now a standard aspect of the preclinical evaluation of new entities of chemicals, as established by the International Conference of Harmonization Expert Working Group for all medications in development.

Surprisingly, nearly 10% of drugs have been withdrawn from the clinical market globally due to cardiovascular safety concerns in the last four decades, including tegaserod, rofecoxib, and sibutramine, despite significant efforts to detect cardiotoxicity in the preclinical phase of medicinal product development, cardiotoxicity continues to be a major source of safety concerns, owing to a lack of sufficient knowledge about cardiotoxicity mechanisms.

Detailed Segmentation –

The global drug-induced cardiotoxicity market is segmented on the basis of – Indication, End-User, and Region. Represented below is a detailed segmental description:

Based on Indications:

• Left Ventricle Dysfunction
• Anthracyclines
• Trastuzumab
• Lapatinib
• ABL Inhibitors
• Bortezomib
• Rhythm Disturbances
• Ischaemia
• Fluoropyrimidines
• Taxanes
• Bevacizumab
• Sorafenib

Based on End-Users:

• Hospitals
• Clinics
• Ambulatory Surgical Centers (ASCs)

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

Drivers for the Global Drug-induced Cardiotoxicity Market:

The use of targeted anticancer medicines has had a positive impact on drug-induced cardiotoxicity industry advancements. There has been an increase in the number of patients recuperating from cancer in many countries throughout the world, which has resulted in an increase in oncology research, which will lead to a reduction in cardiovascular illnesses. As a result, most doctors around the world benefit from increased cancer research activities as the market for drug-induced cardiotoxicity advances.

Drug-induced cardiotoxicity therapy products are in high demand due to increasing life expectancy and healthcare spending in both developed and developing countries. These are certain factors that will help augment this target market’s revenue growth trajectory in the years to come.

Opportunity for the Global Drug-induced Cardiotoxicity Market:

Booming geriatric populations, which are commonly affected with various types of cancer and cardiovascular disorders. This factor is expected to increase opportunities for industry players improve their prospects of amplifying their existing sales figures. This in turn, is expected to foster the development of novel drugs that may eventually lead to greater market growth opportunities.

Restraints for the Global Drug-induced Cardiotoxicity Market:

The further expansion of the global drug-induced cardiotoxicity market is projected to be hampered by stringent enforced regulations for drug approval. Additionally, weaker economic conditions in regions such as the Middle East and Africa have a lower rate of diagnosis and treatment uptake, thereby also posing a challenge to the global drug-induced cardiotoxicity market’s financial growth. Moreover, a lack of sufficient information and expertise about drug-induced cardiotoxicity could restrict the revenue growth of this market.

Competitive Landscape –

Key players in this market are –

• St. Jude Maedical Plc
• Terumo Cardiovascular Systems Corporation
• Biotronik
• Medtronic Plc
• Boston Scientific Corporation
• Johnson & Johnson
• others

These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edges.

For the Drug-induced Cardiotoxicity Market research study, the following years have been considered to estimate the market size: